31 January 2011 /About us
Our website laegemiddelstyrelsen.dk (dkma.dk) has been redesigned with a new look, a new and improved content structure as well as more accurate and relevant search results. The goal has been to develop an appealing and more logical website where you can find what you are looking for quickly.
31 January 2011 /Product information
Potential contamination of alcohol preparation pads, swabs and swabsticks manufactured by Triad Group in the USA
The Danish Medicines Agency warns about potential contamination of prep pads, swabs and swabsticks with the bacteria ‘Bacillus cereus’.
25 January 2011 /Side effects and trials
Please note that, as part of the European Medicines Agency’s domain name change from 'EMEA’ to 'EMA’, adverse reaction reporting systems will need to be updated in order to still send E2B files.
24 January 2011 /Side effects and trials
Information for doctors and dialysis patients regarding peritoneal dialysis solutions from Baxter A/S
As announced previously, there is presently an increased risk that peritoneal dialysis patients could develop aseptic peritonitis (inflammation of the peritoneum). Doctors and patients should still be alert to symptoms suggestive of aseptic peritonitis and should report any cases of aseptic peritonitis in peritoneal dialysis patients.
17 January 2011 /Side effects and trials
No acknowledgement message is currently dispatched when companies submit electronic adverse reaction reports
Since Thursday 13 January, the Danish Medicines Agency has experienced problems with dispatching acknowledgement messages (ACKs) for electronic adverse reaction reports submitted by companies. We are doing all we can to solve the problem fast so that we can send the ACKs that are awaiting.
11 January 2011 /Prices and reimbursement
On 22 December 2009, the Danish Medicines Agency announced that it would begin reassessing the reimbursement status of medicines in ATC group N
04 January 2011 /News - miscellaneous
The Danish Medicines Agency once again puts focus on the risk of weight-loss products containing the active substances ephedrine, rimonabant and sibutramine - weight-loss products that have not been authorised by the authorities.